CryoPort (CYRX) Expected to Announce Quarterly Earnings on Thursday

CryoPort (NASDAQ:CYRX) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $48.66 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The firm had revenue of $48.97 million during the quarter, compared to analyst estimates of $48.18 million. On average, analysts expect CryoPort to post ($0.83) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

CryoPort Trading Up 1.4%

Shares of NASDAQ:CYRX opened at $16.45 on Wednesday. CryoPort has a 1-year low of $7.61 and a 1-year high of $18.88. The firm has a market capitalization of $833.19 million, a PE ratio of -18.28 and a beta of 1.89. The business’s 50 day moving average is $16.94 and its 200-day moving average is $13.36.

Analysts Set New Price Targets

CYRX has been the subject of a number of recent research reports. Needham & Company LLC upped their target price on CryoPort from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Guggenheim lifted their price target on shares of CryoPort from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. BTIG Research boosted their price target on shares of CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Piper Sandler raised shares of CryoPort to a “buy” rating in a report on Tuesday, October 13th. Finally, Robert W. Baird set a $26.00 price objective on shares of CryoPort in a research note on Tuesday, October 13th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, CryoPort presently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

Insiders Place Their Bets

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of CryoPort stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the sale, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.